Clinical trial · Observational
Evaluating the Treatment Outcomes of Tafasitamab in Patients With Relapsed/ Refractory Diffuse Large B-cell Lymphoma: a Real-world Evidence Study
NCT07709624CI-TRIAL-00118289active not recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To evaluate the efficacy of tafasitamab in patients with relapsed/ refractory diffuse large B-cell lymphoma \*To evaluate best objective response rate (ORR)
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| DLBCL | Diffuse Large B-Cell Lymphoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Minjuvi | Drug | Tafasitamab | ALIAS |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- objective response rate (ORR)
- timeFrame
- The time from day 1 of tafasitamab treatment initiation to documented disease progression or death
- description
- the proportion of patients achieving a complete or partial response to tafasitamab, based on the Lugano 2014 criteria.
Secondary outcomes (6)
- measure
- PFS (Progression-Free Survival)
- timeFrame
- defined as the time from day 1 of tafasitamab treatment initiation to documented disease progression or death from any cause.
- measure
- OS (Overall Survival)
- timeFrame
- the time from day 1 of tafasitamab treatment initiation to death from any cause.
- measure
- DoR (Duration of Response)
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Adult patients aged ≥18 years at the time of tafasitamab initiation. 2. Patients who were initiated on tafasitamab treatment between August 1, 2024, and December 31, 2028. 3. Patients with a histologically confirmed diagnosis of DLBCL. 4. Patients ineligible for ASCT based on clinical judgment, comorbidities, or other relevant factors. 5. Patients must have relapsed or refractory disease following at least one prior systemic regimen for DLBCL, with at least one line of therapy including a CD20-targeted agent (e.g., rituximab). Exclusion Criteria: 1\. Patients who are alive but unable or unwilling to provide written informed consent. \-
References
Publications (0)
Data not yet available
No reference posted for this study.